Landau Jeffrey B 4
4 · CytomX Therapeutics, Inc. · Filed Jul 21, 2022
Insider Transaction Report
Form 4
Landau Jeffrey B
Chief Business Officer
Transactions
- Award
Common Stock
2022-07-19+11,250→ 34,931 total - Sale
Common Stock
2022-07-20$1.42/sh−4,206$5,982→ 30,725 total
Holdings
- 4,500(indirect: By IRA)
Common Stock
- 3,180(indirect: By IRA)
Common Stock
Footnotes (4)
- [F1]Represents Performance Stock Units ("PSUs") initially granted on October 24, 2021 that were subject to a performance-based vesting condition. The first milestone vesting condition was determined to be satisfied upon which 50% of the PSUs vested.
- [F2]Includes 16,274 restricted stock units.
- [F3]Reflects the adjusted total which includes the purchase of 5,040 shares under the Cytomx Therapeutics Employee Stock Purchase Plan on May 31, 2022.
- [F4]The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to a PSU of the Issuer.